Resource Tracking

The HIV Vaccines and Microbicides Resource Tracking Working Group was founded in 2004 to track global resources dedicated to the research and development of new biomedical tools for HIV prevention. The Working Group is a collaboration between AVAC: Global Advocacy for HIV Prevention, IAVI and the Joint United Nations Programme on HIV/AIDS (UNAIDS). Funding data assembled by the Working Group date back to 2000 and have enabled the systematic tracking of investments and trends in the advancement of new tools and strategies to prevent HIV.

The most recent report, From Research to Reality: Investing in HIV Prevention Research in a Challenging Landscape (PDF), was issued in July 2013. It covers investments through 2012 on preventive and therapeutic vaccines against HIV, microbicides, adult male circumcision, female condoms, pre-exposure prophylaxis (PrEP), and HSV-2  prevention, as well as developing and improving strategies for prevention of mother-to-child vertical HIV transmission at birth and during breastfeeding.

Global preventive HIV vaccine R&D investment totaled US$847 million in 2012, with the public sector providing US$707 million (83%), the philanthropic sector providing US$110 million (13%) and the commercial sector contributing US$30 million (3%). The 2012 total investment represents a modest increase of US$2 million (1%) over global preventive HIV vaccine R&D investment in 2011. In relation to HIV prevention funding as a whole, the United States government remained the largest donor, and investment grew by US$8 million from 2011. Furthermore, US$52 million came from European public sector agencies. This figure represents a US$3.5 million (1%) increase from the previous year, but funding still is down 37% since 2006. Funding from philanthropic supporters totaled US$110 million, down US$3 million from 2011. Meanwhile, estimated commercial funding in 2012 remained level at US$30 million. The HIV vaccine field has produced an abundance of promising data in recent years. However, given the long-term nature of HIV vaccine development, its continued progress will require flexible and sustained investments in research and development.

HIV Vaccine Funding, 2000-2012


For more information on the Working Group, archived reports and materials, and information on its members, please visit http://www.hivresourcetracking.org.